Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2008695 | 0.98 | PABPC1 (0.45) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL13781535 | 0.96 | PABPC1 (0.46) | PABPC1KMT2AATMLMNAGGPS1 | |
| Bromide SCHEMBL22366470 | 0.92 | KMT2A (0.47) | PABPC1KMT2AATMLMNAGGPS1 | |
| Hydrochloric Acid SCHEMBL11741127 | 0.89 | RAD52 (0.44) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL6114658 | 0.85 | PABPC1 (0.50) | PABPC1KMT2AATMLMNAGGPS1 | |
| Hydrochloric Acid SCHEMBL30330891 | 0.82 | RAD52 (0.47) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL8739576 | 0.81 | KDM4E (0.53) | PABPC1KMT2AATMLMNAKDM4E | |
| SCHEMBL16673982 | 0.81 | KDM4E (0.48) | PABPC1KMT2AATMLMNAGGPS1 | |
| Hydrochloric Acid SCHEMBL17926383 | 0.81 | RAD52 (0.53) | KMT2ALMNAKDM4EALDH1A1APAF1 | |
| Hydrochloric Acid SCHEMBL7251991 | 0.80 | PABPC1 (0.47) | PABPC1KMT2AATMLMNAGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346528-B1 | NICOTINE IMMUNONANOTHERAPEUTICS | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8932595-B2 | Nicotine immunonanotherapeutics | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-01-13 | — | — | US | disclosed |
| US-8591905-B2 | Nicotine immunonanotherapeutics | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130142821-A1 | Hapten-Carrier Conjugates and Uses Thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8187607-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20120027808-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-02-02 | — | — | US | disclosed |
| EP-2392345-A2 | Hapten-carrier conjugates comprising virus like particles and uses thereof | Cytos Biotechnology AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2346528-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | Massachusetts Institute of Technology (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010122164-A1 | VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5 | CYTOS BIOTECHNOLOGY AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100129395-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| WO-2010042866-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-04-15 | — | — | WO | disclosed |
| US-7452541-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050281845-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-12-22 | — | — | US | disclosed |
| US-6932971-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2005-08-23 | — | — | US | disclosed |
| EP-1523334-A2 | HAPTEN-CARRIER CONJUGATES AND USES THEREOF | Cytos Biotechnology AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-20040059094-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2004-03-25 | — | — | US | disclosed |
| WO-2004009116-A2 | HAPTEN-CARRIER CONJUGATES COMPRISING VIRUS LIKE PARTICLES AND USES THEREOF | CYTOS BIOTECHNOLOGY AG (CH) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027808-A1 | NICOTINE IMMUNONANOTHERAPEUTICS | CD47, CD4, FCGR3B | PABPC1 3926/4885KMT2A 2913/4885ATM 4367/4885 |
| US-20100092425-A1 | Nicotine Immunonanotherapeutics | CD4, CD47, FCGR3B | PABPC1 3907/4885KMT2A 3001/4885ATM 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.